Northern Trust Corp Krystal Biotech, Inc. Transaction History

Northern Trust Corp

$600 Billion
Q3 2024

A detailed history of Northern Trust Corp transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 238,691 shares of KRYS stock, worth $42.5 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

238,691

Previous 218,461 9.26%

Holding current value

$42.5 Million

Previous $40.1 Million 8.19%

% of portfolio

0.01%

Previous 0.01%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$174.7 - $213.66 $3.53 Million - $4.32 Million	20,230 Added 9.26%	238,691 $43.4 Million
Q2 2024 Aug 14, 2024	BUY	$153.12 - $183.64 $2.05 Million - $2.46 Million	13,383 Added 6.53%	218,461 $40.1 Million
Q1 2024 May 14, 2024	SELL	$108.01 - $179.35 $445,109 - $739,101	-4,121 Reduced 1.97%	205,078 $36.5 Million
Q4 2023 Feb 13, 2024	SELL	$96.0 - $128.29 $390,144 - $521,370	-4,064 Reduced 1.91%	209,199 $26 Million
Q3 2023 Nov 13, 2023	BUY	$108.51 - $130.22 $448,037 - $537,678	4,129 Added 1.97%	213,263 $24.7 Million
Q2 2023 Aug 11, 2023	BUY	$78.48 - $130.32 $600,921 - $997,860	7,657 Added 3.8%	209,134 $24.6 Million
Q1 2023 May 15, 2023	BUY	$72.39 - $84.27 $13,681 - $15,927	189 Added 0.09%	201,477 $16.1 Million
Q4 2022 Feb 13, 2023	SELL	$63.14 - $79.9 $59,983 - $75,905	-950 Reduced 0.47%	201,288 $15.9 Million
Q3 2022 Nov 14, 2022	BUY	$64.85 - $82.4 $76,523 - $97,232	1,180 Added 0.59%	202,238 $14.1 Million
Q2 2022 Aug 12, 2022	BUY	$48.93 - $73.47 $340,357 - $511,057	6,956 Added 3.58%	201,058 $13.2 Million
Q1 2022 May 13, 2022	BUY	$51.99 - $72.11 $548,130 - $760,255	10,543 Added 5.74%	194,102 $12.9 Million
Q4 2021 Feb 08, 2022	BUY	$39.81 - $88.24 $84,596 - $187,510	2,125 Added 1.17%	183,559 $12.8 Million
Q3 2021 Nov 15, 2021	SELL	$52.01 - $71.77 $370,363 - $511,074	-7,121 Reduced 3.78%	181,434 $9.47 Million
Q2 2021 Aug 13, 2021	BUY	$62.14 - $81.82 $615,993 - $811,081	9,913 Added 5.55%	188,555 $12.8 Million
Q1 2021 May 12, 2021	BUY	$59.42 - $85.46 $327,760 - $471,397	5,516 Added 3.19%	178,642 $13.8 Million
Q4 2020 Feb 11, 2021	SELL	$40.64 - $61.38 $174,670 - $263,811	-4,298 Reduced 2.42%	173,126 $10.4 Million
Q3 2020 Nov 16, 2020	BUY	$37.76 - $48.49 $468,828 - $602,051	12,416 Added 7.52%	177,424 $7.64 Million
Q2 2020 Aug 14, 2020	BUY	$37.03 - $60.0 $606,144 - $982,140	16,369 Added 11.01%	165,008 $6.84 Million
Q1 2020 May 14, 2020	BUY	$35.02 - $65.64 $316,755 - $593,713	9,045 Added 6.48%	148,639 $6.43 Million
Q4 2019 Feb 14, 2020	SELL	$33.17 - $65.23 $114,602 - $225,369	-3,455 Reduced 2.42%	139,594 $7.73 Million
Q3 2019 Nov 13, 2019	BUY	$34.72 - $51.3 $3.58 Million - $5.29 Million	103,065 Added 257.77%	143,049 $4.97 Million
Q2 2019 Aug 13, 2019	BUY	$27.2 - $41.2 $504,832 - $764,672	18,560 Added 86.63%	39,984 $1.61 Million
Q1 2019 May 13, 2019	SELL	$19.86 - $32.9 $8,361 - $13,850	-421 Reduced 1.93%	21,424 $705,000
Q4 2018 Feb 12, 2019	BUY	$15.03 - $25.38 $328,330 - $554,426	21,845 New	21,845 $454,000

Others Institutions Holding KRYS

# of Institutions

310

Shares Held

24.4M

Call Options Held

483K

Put Options Held

364K

View Full List

About Krystal Biotech, Inc.

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $4.57B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

More about KRYS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.

Account

Northern Trust Corp Krystal Biotech, Inc. Transaction History